Opus Genetics (IRD) EBT Margin (2010 - 2026)

Opus Genetics (IRD) has 8 years of EBT Margin data on file, last reported at 3038.25% in Q1 2026.

• On a quarterly basis, EBT Margin fell 285074.0% year-over-year to 3038.25% in Q1 2026; TTM through Mar 2026 was 892.36%, a 46295.0% decrease from a year earlier, with the FY2025 full-year figure at 349.33%, up 17407.0% from the prior year.
• EBT Margin for Q1 2026 stood at 3038.25%, down from 427.5% in the prior quarter.
• Over the last five years, EBT Margin for IRD reached as high as 85.96% in Q4 2022 and fell as low as 3038.25% in Q1 2026.
• Historically, EBT Margin has averaged 515.69% across 5 years, with a median of 307.39% in 2023.
• Across the five-year window, EBT Margin surged 44083 bps in 2025 and sank 285074 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 85.96% in 2022, then slumped by 430 bps to 283.68% in 2023, then slumped by 188 bps to 816.71% in 2024, then soared by 48 bps to 427.5% in 2025, then slumped by 611 bps to 3038.25% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 3038.25% in Q1 2026, 427.5% in Q4 2025, and 566.87% in Q3 2025.